Back to News
Market Impact: 0.25
DualityBio, Genentech Enter Global Deal To Develop Next-Gen ADCs
Source: Nasdaq
Healthcare & BiotechTechnology & InnovationCompany FundamentalsProduct Launches
Duality Biotherapeutics (9606.HK) announced a global collaboration and license agreement with Genentech (Roche) to develop next-generation antibody-drug conjugates (ADCs) using DualityBio’s proprietary DUP platform. The deal is a positive validation of the technology and supports future pipeline development, though no financial terms or timeline were disclosed in the provided text.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- ‘If nothing is done, it’s almost inevitable’: Ukraine’s Yuriy Ryzhenkov on why steelmaking is on the brink of collapse as Russian bombing intensifies
- Why is LG Innotek stock plunging today?
- TotalEnergies, KKR expand U.S. solar venture with 700 MW addition
- Why is SK Hynix stock sliding today?
- TSMC expected to report sixth straight quarter of record profit thanks to AI boom
- Vår Energi cuts 2026 output forecast; Q3 production at 369,000 boepd
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- The $4.7 Trillion Bet: When Does AI Capex Become AI Revenue?
- Equity Research Automation Statistics: A 2026 Evidence Check